Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Alpha Tau (DRTS) Stock Price & Analysis

0 Followers

DRTS Stock Chart & Stats

ILA 4,440.00ILA 1.00(0.02%)
At close:
ILA 4KILA 4.25KILA 4.5KILA 4.75KAug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
ILA 4,362.00 - ILA 4,587.00
52-Week Range
ILA 3,885.00 - ILA 4,977.00
Previous Close
ILA 4,439.00
Volume
N/A
Average Volume (3M)
41.76K
Market Cap
ILS 4.01B
Enterprise Value
ILS 1.05B
Total Cash (Recent Filing)
ILS 100.64M
Total Debt (Recent Filing)
ILS 15.15M
Price to Earnings (P/E)
―
Beta
0.21
Next Earnings
Nov 24, 2026 (Est.)
EPS Estimate
-46.43
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Localized Alpha Radiation

Alpha DaRT’s localized delivery approach addresses a central challenge in cancer treatment: destroying tumor tissue while limiting harm to healthy areas. If clinical evidence supports this intended profile, the technology could provide a differentiated platform applicable across multiple solid-tumor indications.

Expanded Glioblastoma Trial

FDA authorization to expand REGAIN increases the amount of clinical evidence Alpha Tau can generate in recurrent glioblastoma and broadens eligibility to IDH-mutant grade 4 tumors. Additional endpoints and interim analysis may strengthen the regulatory development strategy.

Pancreatic Program Progress

Completion of the multicenter IMPACT study moves Alpha Tau’s pancreatic cancer program from recruitment toward follow-up and data maturation. The enrolled cohort is intended to inform a pivotal study, while the international network supports broader clinical development of Alpha DaRT.

Bears Say

No Revenue And Widening Losses

The absence of revenue and widening losses show that Alpha Tau remains dependent on development spending rather than an established commercial business. Without a revenue ramp, operating expenses may continue to pressure earnings and delay the transition to self-funded growth.

Persistent Cash Burn

Sustained negative operating and free cash flow means Alpha Tau is consuming cash while advancing its clinical pipeline. Continued outflows increase reliance on external funding, creating financing and potential dilution pressure if losses persist through later-stage development.

Unapproved Clinical Technology

Because Alpha DaRT lacks approval for routine clinical use, its long-term commercial potential remains contingent on successful trials and regulatory decisions. This keeps the business exposed to development setbacks and extends the period before recurring product revenue can emerge.

Alpha Tau News

DRTS FAQ

What was Alpha Tau’s price range in the past 12 months?
Alpha Tau lowest stock price was ILA 3885.00 and its highest was ILA 4977.00 in the past 12 months.
What is Alpha Tau’s market cap?
Alpha Tau’s market cap is ₪4.01B.
When is Alpha Tau’s upcoming earnings report date?
Alpha Tau’s next earnings report is estimated for Nov 24, 2026 (not yet confirmed), which is in 13 days.
How were Alpha Tau’s earnings last quarter?
Alpha Tau released its earnings results on Aug 10, 2026. The company reported -ILA 157.939 earnings per share for the quarter, missing the consensus estimate of -ILA 44.539 by -ILA 113.401.
Is Alpha Tau overvalued?
According to Wall Street analysts Alpha Tau’s price is currently Undervalued.
Does Alpha Tau pay dividends?
Alpha Tau does not currently pay dividends.
What is Alpha Tau’s EPS estimate?
Alpha Tau’s EPS estimate is -46.43.
How many shares outstanding does Alpha Tau have?
Alpha Tau has 92,478,160 shares outstanding.
What happened to Alpha Tau’s price movement after its last earnings report?
Alpha Tau reported an EPS of -ILA 157.939 in its last earnings report, missing expectations of -ILA 44.539. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Alpha Tau?
Hedge funds hold Alpha Tau shares: hedge funds decreased their holdings by 15.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology